Regor Pharmaceuticals USA has entered into a definitive purchase agreement, under which Genentech, a member of the Roche Group, will acquire a portfolio of next-generation CDK inhibitors from Regor for the treatment of breast cancer. Regor will receive an upfront cash payment of $850 million and is eligible to receive additional cash payments. Genentech will be responsible for clinical development, manufacturing and commercialization.
Regor Pharmaceuticals USA is part of Regor Therapeutics Group, a clinical-stage biotechnology company developing clinically differentiated medicines to address large unmet needs in oncology, metabolism and auto-immunity.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.